Miaoshou Doctor, the China-based telemedicine platform developer backed by internet group Tencent, secured RMB200m ($84.5m) in series D1 funding today.
The round was revealed by venture capital firm Qiming Partners through an announcement on its WeChat account. Qiming invested alongside Ince Capital, Sequoia Capital China, Citic Securities and Index Capital.
Formally known as Beijing Yuanxin Technology, Miaoshou Doctor operates an online platform that enables patients to schedule remote meetings with doctors through phone or video calls in addition to getting prescriptions filled and purchasing health insurance.
The company will channel the series D1 proceeds into expanding the range of services it provides, and in particular improving its insurance offering.
Tencent invested an eight-figure renminbi (RMB10m = $1.6m) amount in the company in 2015 before leading a $79.3m series C round in April 2018 that included Qiming, Sequoia China and Kun Ling Capital, through its Shenzhen Tencent Investment Fund.
Starquest Capital led a $73m series C-plus round for Miaoshou Doctor in January 2019 that included Sequoia China before joining unnamed existing investors in a round of undisclosed size six months later that valued the company at $1bn.
